Home › Research › Treatments
Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025)
Lorena Guadalupe Delvalle Rotela, Katherinne Ailen Sanchez Olmedo. Zenodo (CERN European Organization for Nuclear Research), 2026-09-14
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA).
What this study adds
Evidence grade: Low
This literature review aims to analyse the efficacy of lecanemab as a disease-modifying therapy for Alzheimer's disease. No results or conclusions are provided in the available text.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rotela, L. G. D., & Olmedo, K. A. S. (2026). Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025). Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.22756412
Vancouver
Rotela LGD, Olmedo KAS. Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025). Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.22756412.
BibTeX
@article{rotela2026-cf778e0b,
author = {Rotela, Lorena Guadalupe Delvalle and Olmedo, Katherinne Ailen Sanchez},
title = {{Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025)}},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
doi = {10.5281/zenodo.22756412},
url = {https://doi.org/10.5281/zenodo.22756412}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA).
Why it matters
This literature review aims to analyse the efficacy of lecanemab as a disease-modifying therapy for Alzheimer's disease. No results or conclusions are provided in the available text.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 26 of the 92 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Zenodo (CERN European Organization for Nuclear Research)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Katherinne Ailen Sanchez Olmedo holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Universidad Gran Asunción: institution h-index 15 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 92 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 26 of the 92 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.5281/zenodo.22756412
- Original source →
- Free full text: Zenodo (CERN European Organization for Nuclear Research) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
194 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.